Evidence map›Paper›PMID 42078457›Full record

ArticleFrontiers in medicine2026

A patient with CKD complicated by secondary hyperparathyroidism and parathyroid carcinoma: a case report.

Wenxia Wang, Qiuchao Jin, Chengmin Huang

Abstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wenxia Wang *Changxing County People's Hospital, Huzhou, Zhejiang, China.
Qiuchao Jin *Changxing County People's Hospital, Huzhou, Zhejiang, China.
Chengmin HuangChangxing County People's Hospital, Huzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Parathyroid carcinoma (PC) is a rare malignancy, representing approximately 0.005% of all malignant tumors. Currently, its etiopathogenesis, diagnostic criteria, and optimal management strategies remain poorly defined. Furthermore, the occurrence of PC in the context of secondary hyperparathyroidism (SHPT) is an infrequent clinical event. This report details a case of PC arising in a patient with chronic kidney disease (CKD) and SHPT. Case presentation: A 53-year-old male with severe renal failure was admitted for clinical evaluation. During the course of hospitalization, SHPT and PC were diagnosed based on clinical, biochemical, and imaging evaluations. Intraoperative pathological assessment confirmed the malignancy, necessitating radical resection with regional lymph node dissection. The patient has achieved a long term disease free survival exceeding 8 years after surgery. Conclusion: The diagnosis of PC remains clinically challenging due to its rarity and the significant overlap in biochemical and imaging features with benign parathyroid lesions. This diagnostic challenge is further intensified in patients with severe renal insufficiency, as characteristic clinical indicators are often masked by comorbid secondary hyperparathyroidism. This report illustrates the diagnostic process and successful long-term management of PC in this challenging context, providing a clinical reference for the standardized treatment of this rare malignancy.

Indexed as

case reportchronic kidney diseasemalignancyparathyroid carcinomasecondary hyperparathyroidism

Identifiers

PMID42078457
PMCPMC13128398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.